fructose--bisphosphatase opposes renal carcinoma progression 
clear cell renal cell carcinoma ccrcc common form kidney cancer1 characterized elevated glycogen levels fat deposition2 consistent metabolic alterations associated normoxic stabilization hypoxia-inducible factors hifs3 secondary von hippel-lindau vhl mutations occur % ccrcc tumours4 however kidney-specific vhl deletion mice fails elicit ccrcc-specific metabolic phenotypes tumour formation5 suggesting additional mechanisms essential recent large-scale sequencing analyses revealed loss several chromatin remodelling enzymes subset ccrcc included polybromo- set domain containing brca1 associated protein- among others6- indicating epigenetic perturbations probably important contributors natural history disease used integrative approach comprising pan-metabolomic profiling metabolic gene set analysis determined gluconeogenic enzyme fructose--bisphosphatase fbp110 uniformly depleted six hundred ccrcc tumours examined notably human fbp1 locus resides chromosome 9q22 loss associated poor prognosis ccrcc patients" data indicate fbp1 inhibits ccrcc progression two distinct mechanisms first fbp1 antagonizes glycolytic flux renal tubular epithelial cells presumptive ccrcc cell origin12 thereby inhibiting potential warburg effect1314 second pvhl protein encoded vhl gene-deficient ccrcc cells fbp1 restrains cell proliferation glycolysis pentose phosphate pathway catalyticactivity-independent manner inhibiting nuclear hif function via direct interaction hif inhibitory domain unique dual function fbp1 protein explains ubiquitous loss ccrcc distinguishing fbp1 previously identified tumour suppressors consistently mutated tumours6715 
